UK'S MHRA: AUTHORISES CANCER TREATMENT VARIATION WITH AN ADMINISTRATION TIME OF 3–5 MINUTES - WEBSITE
UK'S MHRA: APPROVED NEW UNDER-THE-SKIN INJECTION VERSION OF NIVOLUMAB (OPDIVO)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.